Gestational Diabetes

• Placental hormone-induced insulin resistance: The placenta secretes increasing quantities of human placental lactogen (hPL), progesterone, prolactin, and cortisol—all potent insulin antagonists. hPL rises progressively throughout pregnancy and is directly proportional to placental mass; it antagonizes insulin by competing for receptor binding and inhibiting glucose uptake in insulin-sensitive tissues. Progesterone decreases hepatic insulin extraction and impairs pancreatic beta cell function. This combination creates a state of "accelerated starvation" in the fasted state and postprandial hyperglycemia in the fed state. In normal pregnancy, healthy women compensate by increasing insulin secretion by 200-300% through enhanced beta cell proliferation and increased insulin gene expression, maintaining euglycemia. Women who develop GDM fail to mount adequate compensatory beta cell hyperfunction, revealing underlying beta cell dysfunction and/or severe insulin resistance.

• Adipose tissue insulin resistance and lipid metabolism dysfunction: Pregnancy-induced changes in adipose tissue, mediated by increased estrogen and progesterone, promote lipolysis and fatty acid oxidation. Free fatty acids (FFAs) accumulate in maternal circulation, accumulating particularly in hepatic and skeletal muscle tissues where they suppress insulin signaling through the inhibitor of nuclear factor kappa-B kinase subunit beta (IKKβ) and c-Jun N-terminal kinase (JNK) pathways—causing insulin receptor substrate (IRS)-1 phosphorylation and degradation and reducing downstream phosphatidylinositol 3-kinase (PI3K) signaling. Additionally, triglycerides increase 2-3 fold in pregnancy, further exacerbating lipid-induced insulin resistance. Adiponectin levels decrease in pregnancy, removing a crucial insulin-sensitizing adipokine.

• Inflammatory cytokine dysregulation and metabolic endotoxemia: Pregnancy induces a state of mild systemic inflammation characterized by elevated interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP). In GDM, this inflammatory response is exaggerated; elevated TNF-α suppresses IRS-1 and reduces glucose transporter 4 (GLUT4) translocation. Additionally, lipopolysaccharide (LPS) from gram-negative gut bacteria increases in pregnancy, activating toll-like receptor 4 (TLR4) on macrophages and adipocytes, triggering NF-κB-mediated proinflammatory cascades that further impair insulin signaling. Abnormal placental inflammatory infiltration and elevation of placental inflammatory markers (IL-6, TNF-α) characterize GDM pregnancies.

• Genetic predisposition and beta cell dysfunction: Multiple candidate genes have been associated with GDM susceptibility, including variants in TCF7L2, HHEX, CDKN1A, and genes encoding potassium channel subunits. These variants impair beta cell function and glucose sensing. Additionally, women with GDM demonstrate reduced beta cell proliferation and increased apoptosis compared to normal pregnancy. Placental lactogen and progesterone, while stimulating beta cell proliferation through cyclin-dependent kinase pathways in healthy pregnancies, paradoxically may exacerbate beta cell dysfunction in genetically predisposed women. Epigenetic modifications—including altered DNA methylation patterns and histone acetylation—contribute to impaired beta cell gene expression in GDM.

• Fetal hyperglycemia-hyperinsulinemia and metabolic consequences: Maternal hyperglycemia crosses the placenta via the glucose transporter GLUT1, which is not insulin-dependent. Fetal hyperglycemia stimulates fetal pancreatic beta cells to produce excessive insulin (since the fetal pancreas responds to glucose but insulin cannot cross the placenta). Fetal hyperinsulinemia drives nutrient uptake and storage, causing fetal macrosomia (excess adiposity and organomegaly). At delivery, removal of the transplacental glucose supply causes abrupt neonatal hyperinsulinemia to persist briefly, causing severe neonatal hypoglycemia as fetal insulin suppresses hepatic glucose production and increases glucose utilization. Additionally, maternal hyperglycemia impairs fetal lung maturation by suppressing surfactant production and increasing pulmonary edema risk.

• Maternal obesity and metabolic syndrome (BMI >30 kg/m²): Obesity exacerbates pregnancy-induced insulin resistance through multiple mechanisms including increased FFA delivery, expanded visceral adiposity, enhanced inflammatory cytokine production, and mitochondrial dysfunction. Obese women have baseline reduced adiponectin and increased leptin resistance. Pre-pregnancy BMI is the single strongest modifiable risk factor; women with BMI >35 kg/m² have 3-4 fold increased GDM risk. Metabolic syndrome components (hypertension, dyslipidemia, central obesity) independently predict GDM. Gestational weight gain above Institute of Medicine recommendations further increases risk.

• Maternal age >35 years: Advanced maternal age is associated with reduced beta cell function, increased insulin resistance, and accumulation of metabolic comorbidities. Women >35 have 1.5-2 fold increased GDM risk compared to women <25. This may reflect both chronological aging of beta cells and confounding by increased obesity prevalence.

• Ethnicity and genetic ancestry: GDM prevalence varies dramatically by ethnicity, with highest rates in Hispanic/Latino (15-20%), Native American (5-10%), Asian (10-15%), and South Asian populations (10-20%), compared to 2-5% in non-Hispanic white populations. This reflects both genetic predisposition (higher frequency of susceptibility alleles in these populations, as demonstrated by genome-wide association studies) and environmental factors including obesity prevalence and dietary patterns. Women with first-degree relatives with type 2 diabetes have 2-3 fold increased risk.

• Personal history of GDM: Approximately 20-50% of women with prior GDM develop type 2 diabetes within 5-10 years after delivery, reflecting underlying persistent beta cell dysfunction and insulin resistance. Recurrence of GDM in subsequent pregnancies occurs in 30-50% of women.

• Polycystic ovary syndrome (PCOS): Women with PCOS have baseline insulin resistance, hyperandrogenism, and impaired beta cell function. GDM risk is 2-3 fold increased in PCOS. The mechanism involves both insulin resistance and relative beta cell dysfunction.

• Previous delivery of a macrosomic infant or unexplained fetal loss: A prior infant birthweight >4000-4500 g suggests maternal glycemic dysregulation in pregnancy, even if GDM was not diagnosed. Unexplained fetal loss or polyhydramnios in prior pregnancies may indicate undiagnosed GDM.

• Maternal hypertension and dyslipidemia: These components of metabolic syndrome correlate with GDM risk and reflect underlying insulin resistance.

• Asymptomatic hyperglycemia (most common): The majority of women with GDM (70-80%) have no symptoms and are identified through population screening during routine prenatal care. The lack of symptoms reflects the gradual onset and intermediate severity of glucose intolerance compared to type 1 or type 2 diabetes.

• Polyuria and polydipsia (less common, indicates more severe hyperglycemia): When maternal glucose exceeds the renal threshold (~180 mg/dL), glucosuria develops, creating osmotic diuresis and polyuria. This typically occurs only with more severe hyperglycemia or undiagnosed GDM in the third trimester. Compensatory polydipsia may be reported but is often attributed to pregnancy-related symptoms. These symptoms suggest glucose levels consistently >200 mg/dL.

• Recurrent candidal vulvovaginitis: Elevated vaginal glucose due to glucosuria creates an osmotically favorable environment for Candida albicans proliferation. Recurrent vaginal yeast infections in a pregnant woman, particularly if previously uncommon, should raise suspicion for GDM.

• Preeclampsia-like symptoms (gestational hypertension, proteinuria, edema): Women with GDM have 2-3 fold increased risk of preeclampsia. Symptoms include new-onset hypertension (>140/90 mmHg) after 20 weeks, proteinuria, headache, visual changes, and right upper quadrant pain. GDM and preeclampsia share common pathophysiology involving endothelial dysfunction and placental insufficiency.

• Polyhydramnios and uterine distension symptoms: Fetal hyperglycemia and hyperinsulinemia increase fetal urine output (the primary source of amniotic fluid), leading to polyhydramnios in 10-20% of GDM pregnancies. Excessive amniotic fluid causes maternal dyspnea, abdominal discomfort, and premature contractions. Polyhydramnios increases risk of preterm labor and delivery.

• Recurrent pregnancy loss or unexplained stillbirth in prior pregnancies: A history of recurrent miscarriage (particularly second-trimester or later) or unexplained fetal demise may indicate undiagnosed GDM in prior pregnancies, though other etiologies must be excluded.

• Physical examination findings: Typical prenatal examination may show evidence of obesity (BMI >30), acanthosis nigricans (hyperpigmented, velvety skin thickening typically on neck and axillae, indicating severe insulin resistance), or signs of preeclampsia including edema and hypertension. Fundal height may be excessive relative to gestational age, suggesting macrosomia or polyhydramnios. However, physical examination is generally non-diagnostic for GDM.

• Screening approach—two-step method (most common in USA):
• Step 1: Non-fasting 50-gram glucose challenge test (GCT) performed at 24-28 weeks gestation. Any glucose value ≥140 mg/dL (7.8 mmol/L) is considered abnormal; using ≥140 mg/dL detects approximately 80% of women with GDM (sensitivity 80%, specificity 80%). Approximately 15-25% of pregnant women have abnormal GCT. Higher threshold of ≥200 mg/dL (11.1 mmol/L) is 100% specific but misses cases.
• Step 2: Diagnostic 3-hour 100-gram OGTT for women with abnormal GCT. Performed fasting, measuring fasting glucose, and glucose at 1, 2, and 3 hours after 100-gram glucose load. Using Carpenter and Coustan criteria (see below), approximately 15-25% of women with abnormal GCT meet GDM diagnostic criteria.

• One-step approach—2-hour 75-gram OGTT: Increasingly adopted, particularly internationally (WHO recommendation). Performed fasting at 24-28 weeks with a single 75-gram glucose load, measuring fasting glucose and glucose at 1 and 2 hours. Diagnostic threshold: fasting ≥92 mg/dL (5.1 mmol/L) OR 1-hour ≥180 mg/dL (10.0 mmol/L) OR 2-hour ≥153 mg/dL (8.5 mmol/L)—if ANY single value exceeds threshold, GDM is diagnosed. This one-step approach has higher sensitivity (approximately 85%) but lower specificity than two-step method; it identifies more women with milder glucose intolerance, though whether this improves outcomes compared to two-step screening remains debated.

• Carpenter and Coustan criteria for 3-hour 100-gram OGTT (widely used diagnostic standard in USA):
• Fasting: ≥95 mg/dL (5.3 mmol/L)
• 1-hour: ≥180 mg/dL (10.0 mmol/L)
• 2-hour: ≥155 mg/dL (8.6 mmol/L)
• 3-hour: ≥140 mg/dL (7.8 mmol/L)
• Diagnosis requires ≥2 abnormal values

• Fasting plasma glucose (FPG) ≥126 mg/dL (7.0 mmol/L) or random glucose ≥200 mg/dL (11.1 mmol/L) with symptoms: These values indicate overt diabetes rather than gestational diabetes and warrant discussion with endocrinology regarding whether patient has pre-existing type 2 diabetes misclassified as GDM. HbA1c >6.5% (48 mmol/mol) on initial screening indicates pre-existing diabetes.

• Early screening consideration for high-risk women: Women with multiple risk factors (severe obesity BMI >40, strong family history of diabetes, prior GDM, ethnicity with high GDM prevalence, maternal age >40) may be offered earlier screening in first or early second trimester using FPG or HbA1c to identify pre-existing type 2 diabetes. However, most guidelines recommend routine screening at 24-28 weeks regardless.

• Repeat testing: Women with negative initial screening at 24-28 weeks may be re-screened at 32-34 weeks if high risk (obesity, strong family history, prior GDM) as glucose intolerance may emerge later in pregnancy, though this is not routine.

• Differential diagnosis:
• Pre-existing type 2 diabetes: FPG >125 mg/dL, HbA1c >6.5%, or random glucose >200 mg/dL on initial evaluation; should be managed as pre-existing diabetes
• Type 1 diabetes: Presentation with diabetic ketoacidosis, positive autoantibodies (GAD, IA-2, ZnT8), C-peptide <0.8 ng/mL; typically presents with acute symptoms
• Secondary diabetes (pancreatitis, hemochromatosis, pancreatic cancer): Rare; clinical context and imaging usually identify etiology

• Lifestyle modification—first-line for all women with GDM:
• Medical nutrition therapy (MNT): Approximately 85% of women achieve euglycemia with diet alone without pharmacotherapy. Dietary approach emphasizes: (1) carbohydrate quality over quantity—consuming low glycemic index (GI) foods (whole grains, legumes, non-starchy vegetables, fruits with high fiber) rather than simple carbohydrates; (2) portion control—distributing carbohydrates across 3 meals and 2-3 snacks to prevent post-prandial hyperglycemia sp

Fetal and neonatal — driven by fetal hyperinsulinemia

• Macrosomia and large-for-gestational-age growth: insulin is the principal fetal growth factor, so transplacental glucose plus fetal hyperinsulinemia drives asymmetric growth of insulin-sensitive tissues (shoulders, chest, liver) with relative head sparing. Signalled by fundal height exceeding dates and estimated fetal weight above the 90th percentile on ultrasound.
• Shoulder dystocia and birth trauma (obstetric emergency): the disproportionately broad shoulder girdle impacts behind the pubic symphysis. Heralded by the turtle sign; sequelae include Erb-Duchenne palsy (C5-C6, waiter's tip posture), clavicular or humeral fracture, and hypoxic injury. Managed with McRoberts maneuver and suprapubic pressure. ACOG advises offering scheduled cesarean when estimated fetal weight is at or above 4,500 g in a diabetic pregnancy.
• Neonatal hypoglycemia (emergency): abrupt loss of the maternal glucose supply while hyperinsulinemia persists suppresses hepatic glycogenolysis. Jitteriness, poor feeding, or seizures within hours of birth; AAP protocols mandate scheduled heel-stick glucose screening of infants of diabetic mothers.
• Respiratory distress syndrome: hyperinsulinemia antagonizes cortisol-driven surfactant (especially phosphatidylglycerol) synthesis, so lungs mature late for gestational age — grunting, retractions, ground-glass film.
• Polycythemia, hyperbilirubinemia, hypocalcemia/hypomagnesemia: fetal hyperinsulinemia raises oxygen consumption and erythropoietin; the resulting red cell mass breaks down into bilirubin. Hypocalcemia reflects delayed parathyroid transition.
• Polyhydramnios, preterm labor, and stillbirth: osmotic fetal diuresis expands amniotic fluid; late unexplained fetal demise is the rationale for antenatal testing in medication-treated GDM.

Maternal

• Preeclampsia (severe features are an emergency): shared endothelial dysfunction; new hypertension with proteinuria, headache, or right upper quadrant pain after 20 weeks.
• Operative delivery, perineal laceration, and postpartum hemorrhage from uterine overdistension.
• Progression to type 2 diabetes: persistent beta cell dysfunction; ADA Standards of Care require postpartum glucose retesting and lifelong periodic screening.

Treatment-related

• Maternal hypoglycemia from insulin or a sulfonylurea, worsened by aggressive caloric restriction.
• Starvation ketosis/ketonuria from over-restricted carbohydrate intake — check urine ketones.
• Transplacental drug effects: glyburide crosses the placenta and is associated with more neonatal hypoglycemia and macrosomia; metformin also crosses, which is why ACOG and ADA name insulin the preferred agent.

• GDM does not cause congenital malformations: organogenesis is complete before placental insulin resistance peaks. Caudal regression syndrome, transposition of the great vessels, and neural tube defects belong to pregestational diabetes with elevated periconceptional HbA1c. This is the single most common distractor on GDM stems — if the vignette features an anomaly, the answer is undiagnosed pre-existing type 2 diabetes, not GDM.
• Human placental lactogen is the buzzword mechanism: an anti-insulin hormone rising with placental mass, which is why glucose intolerance emerges in the second half of pregnancy and resolves immediately after delivery of the placenta.
• Best next step after delivery: a 75-g 2-hour OGTT at 4–12 weeks postpartum, per the ADA Standards of Care and ACOG — not HbA1c, which is unreliable soon after pregnancy because of altered red cell turnover. Women with normal results still need lifelong rescreening every 1–3 years.
• Insulin is the preferred pharmacotherapy when medical nutrition therapy fails (ACOG, ADA). It does not cross the placenta. Metformin and glyburide both cross; glyburide is associated with more neonatal hypoglycemia and macrosomia.
• The classic delivery-room sequence: jittery, plethoric, large infant of a diabetic mother → check a fingerstick glucose first. Hypoglycemia here is transient hyperinsulinism, not a metabolic inborn error.
• Macrosomia is asymmetric: abdominal and shoulder girdle growth outstrips head growth, which is why shoulder dystocia — and not cephalopelvic disproportion — is the tested complication, and why Erb palsy with a waiter's tip arm is the associated injury.
• The one association examiners love: a woman with prior GDM has a substantial, well-documented lifetime risk of type 2 diabetes; breastfeeding lowers that risk and is actively encouraged.
• Class A1 (diet-controlled) versus A2 (medication-requiring) determines surveillance and timing: A2 GDM warrants antenatal fetal testing and earlier planned delivery, while well-controlled A1 GDM can be managed expectantly toward the due date.